RxDoctor Payments Data

David Harding, MD

Cardiovascular Disease · Greensboro, NCNPI 1457576043

Payments from drug & device makers

$15,349in general payments, 2019–2025

Across 495 payments — averaging $31.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Abiomed$2K
  • Heartflow, Inc.$2K
  • Amgen$1K
  • Novartis$831
  • Shockwave Medical, Inc$786
  • plus $5K from 35 others

What the payments were for

  • Consulting fees$1,87512%
  • Travel & lodging$1,62111%
  • Food & beverage$11,84077%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,349 in reported general payments places this provider in the 75th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$57,285
Medicare patients
386
Services billed
816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban455$459,896
Repatha SureclickEvolocumab273$219,708
XareltoRivaroxaban117$103,449
EntrestoSacubitril/Valsartan104$97,316
BrilintaTicagrelor56$45,050
FarxigaDapagliflozin Propanediol38$33,351
JardianceEmpagliflozin41$28,305
WegovySemaglutide14$18,185
NexlizetBempedoic Acid/Ezetimibe33$15,999
Praluent PenAlirocumab16$11,208
VascepaIcosapent Ethyl14$8,597
Metoprolol Succinate421$5,297
Rosuvastatin Calcium443$5,057
Atorvastatin Calcium337$4,664
Ranolazine ErRanolazine50$4,619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$389$459,896455 claims
Johnson & JohnsonXarelto$270$103,449117 claims
NovartisEntresto$831$97,316104 claims
AstraZenecaBrilinta, Farxiga$689$78,40194 claims
Boehringer IngelheimJardiance$335$28,30541 claims
Novo NordiskWegovy$64$18,18514 claims
Esperion Therapeutics, Inc.Nexlizet$201$15,99933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →